Your Health, We Care
Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response to or intolerance of one or more disease-modifying antirheumatic drugs (DMARDs). It may be used as monotherapy or in combination with methotrexate.
Baricitinib is indicated for the treatment of moderate to severe atopic dermatitis in children aged 2 years and older and adults who are candidates for systemic therapy.
Baricitinib is indicated for the treatment of severe alopecia areata in adults.
Baricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients aged 2 years and older who have had an inadequate response to or intolerance of one or more prior conventional synthetic or biologic DMARDs, including: polyarticular juvenile idiopathic arthritis (rheumatoid factor-positive [RF+] or -negative [RF-], extended oligoarticular), enthesitis-related arthritis, and juvenile psoriatic arthritis. It may be used as monotherapy or in combination with methotrexate.
FDA，2025.01
